Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBITDA: 2018-2025

Historic EBITDA for Whitehawk Therapeutics (WHWK) over the last 7 years, with Sep 2025 value amounting to -$17.6 million.

  • Whitehawk Therapeutics' EBITDA fell 41.15% to -$17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.5 million, marking a year-over-year increase of 74.82%. This contributed to the annual value of -$63.7 million for FY2024, which is 2.93% up from last year.
  • Latest data reveals that Whitehawk Therapeutics reported EBITDA of -$17.6 million as of Q3 2025, which was up 66.51% from -$52.6 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' EBITDA peaked at $73.0 million during Q1 2025, and registered a low of -$87.1 million during Q3 2021.
  • In the last 3 years, Whitehawk Therapeutics' EBITDA had a median value of -$16.3 million in 2023 and averaged -$11.5 million.
  • In the last 5 years, Whitehawk Therapeutics' EBITDA slumped by 2,674.39% in 2021 and then surged by 498.39% in 2025.
  • Over the past 5 years, Whitehawk Therapeutics' EBITDA (Quarterly) stood at -$16.6 million in 2021, then rose by 16.28% to -$13.9 million in 2022, then decreased by 16.49% to -$16.2 million in 2023, then decreased by 12.76% to -$18.3 million in 2024, then crashed by 41.15% to -$17.6 million in 2025.
  • Its EBITDA stands at -$17.6 million for Q3 2025, versus -$52.6 million for Q2 2025 and $73.0 million for Q1 2025.